Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBIT Margin: 2016-2025

Historic EBIT Margin for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to 29.66%.

  • Collegium Pharmaceutical's EBIT Margin rose 779.00% to 29.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.74%, marking a year-over-year decrease of 1155.00%. This contributed to the annual value of 26.91% for FY2024, which is 255.00% down from last year.
  • As of Q3 2025, Collegium Pharmaceutical's EBIT Margin stood at 29.66%, which was up 58.82% from 18.67% recorded in Q2 2025.
  • Collegium Pharmaceutical's EBIT Margin's 5-year high stood at 41.20% during Q4 2023, with a 5-year trough of -124.71% in Q4 2021.
  • Its 3-year average for EBIT Margin is 26.14%, with a median of 26.29% in 2023.
  • As far as peak fluctuations go, Collegium Pharmaceutical's EBIT Margin slumped by 14,437bps in 2021, and later soared by 13,378bps in 2022.
  • Over the past 5 years, Collegium Pharmaceutical's EBIT Margin (Quarterly) stood at -124.71% in 2021, then soared by 13,378bps to 9.07% in 2022, then soared by 3,213bps to 41.20% in 2023, then slumped by 2,025bps to 20.95% in 2024, then skyrocketed by 779bps to 29.66% in 2025.
  • Its last three reported values are 29.66% in Q3 2025, 18.67% for Q2 2025, and 12.20% during Q1 2025.